- Home
- LIXT vs XAIR Comparison
LIXT vs XAIR Comparison
Compare LIXT & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIXT
- XAIR
- Stock Information
- Founded
- LIXT 2005
- XAIR 2011
- Country
- LIXT United States
- XAIR United States
- Employees
- LIXT N/A
- XAIR N/A
- Industry
- LIXT Biotechnology: Pharmaceutical Preparations
- XAIR Medical/Dental Instruments
- Sector
- LIXT Health Care
- XAIR Health Care
- Exchange
- LIXT Nasdaq
- XAIR Nasdaq
- Market Cap
- LIXT 20.5M
- XAIR 17.0M
- IPO Year
- LIXT N/A
- XAIR N/A
- Fundamental
- Price
- LIXT $4.20
- XAIR $1.86
- Analyst Decision
- LIXT
- XAIR Strong Buy
- Analyst Count
- LIXT 0
- XAIR 1
- Target Price
- LIXT N/A
- XAIR $11.00
- AVG Volume (30 Days)
- LIXT 120.3K
- XAIR 233.7K
- Earning Date
- LIXT 11-07-2025
- XAIR 11-10-2025
- Dividend Yield
- LIXT N/A
- XAIR N/A
- EPS Growth
- LIXT N/A
- XAIR N/A
- EPS
- LIXT N/A
- XAIR N/A
- Revenue
- LIXT N/A
- XAIR $4,782,000.00
- Revenue This Year
- LIXT N/A
- XAIR $261.11
- Revenue Next Year
- LIXT N/A
- XAIR $151.82
- P/E Ratio
- LIXT N/A
- XAIR N/A
- Revenue Growth
- LIXT N/A
- XAIR 168.20
- 52 Week Low
- LIXT $0.64
- XAIR $1.81
- 52 Week High
- LIXT $6.26
- XAIR $13.52
- Technical
- Relative Strength Index (RSI)
- LIXT 41.38
- XAIR 34.30
- Support Level
- LIXT $4.05
- XAIR $1.95
- Resistance Level
- LIXT $4.51
- XAIR $2.08
- Average True Range (ATR)
- LIXT 0.34
- XAIR 0.16
- MACD
- LIXT -0.02
- XAIR -0.05
- Stochastic Oscillator
- LIXT 27.27
- XAIR 4.94
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.